BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...
BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...
BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Eq. 6<br />
<br />
Eq. 7<br />
The variables X1, X2, X3, X4, X5 and X6 are to the drug amounts in the central,<br />
absorption, peripheral, two transient compartments and tumor compartments; Ke is<br />
systemic elimination rate constant; Kcp and Kpc are intercompartment rate constants<br />
between peripheral and central compartments; Kct is elimination rate constant from<br />
central compartment to tumor compartment; Kte is elimination rate constant leaving from<br />
tumor compartment; Vc is volume of distribution in central compartment and Vt is<br />
volume of distribution in tumor compartment.<br />
2.2.8 Population pharmacokinetic analysis<br />
Non linear mixed effects modeling using the MLEM algorithm implemented in<br />
ADAPT 5 [181] was used to evaluate the TPT plasma and tumor ECF concentrations. In<br />
the MLEM algorithm, ML is combined with an EM algorithm. The EM algorithm<br />
consists of two steps. In the first step, each individual’s parameters are estimated using<br />
the latest predicted parameter values and the observed data. In the second step, parameter<br />
values are updated to maximize the log-likelihood function in the first step. These two<br />
steps are then iterated until convergence. The initial values for population means and<br />
population covariance matrix (inter-individual variability) were estimated by naïve<br />
pooled analysis. Both population and individual estimates ware determined. The<br />
model-fitted curve for each mouse was used to estimate the area under the<br />
concentration-time curve from time zero to 6 hr in plasma (AUCp) and tumor ECF<br />
(AUCt). The measures of penetration were expressed as AUC tumor-to-plasma ratio<br />
(AUCt/AUCp).<br />
2.2.9 Covariate analysis<br />
A diagnostic screening was done to identify covariates such as the presence of<br />
BEV in the treatment and the different schedules of the combination therapy that<br />
potentially affected TPT PK parameters, including systemic elimination rate Ke,<br />
elimination rate from tumor compartment Kte and volume of distribution in tumor<br />
compartment Vt. These potential covariates were then included in the non-linear<br />
mixed-effects population model to investigate their ability to significantly improve the<br />
model fit (by a reduction of at least 3.84 [p